Intercept Pharmaceuticals Beats on Earnings and Revenue
May 04, 2017: Intercept Pharmaceuticals reports Q1 EPS of -$3.61 versus the -$4.27 estimate. Revenue also beat coming in at $21 million versus the $15.9 million estimate. As of March 31, 2017, Intercept had cash, cash equivalents and investment securities available for sale of approximately $608 million, compared to $689.4 million as of December 31, 2016.
The CEO said that they completed enrollment of Phase 3 REGENERATE trial interim analysis cohort: data expected in 1H 2019.
Anticipated 2017 Milestones:
Ongoing U.S. Ocaliva launch
Launch Ocaliva in key European markets and seek regulatory approval in other target international markets
Continue enrollment of Phase 4 COBALT trial evaluating the effect of Ocaliva on clinical outcomes in PBC
Report CONTROL top-line results in mid-2017
Initiate Phase 3 trial in NASH patients with cirrhosis during 2H 2017
Report AESOP top-line results in mid-2017
Initiate Phase 2 trial for INT-767, a dual FXR/TGR5 agonist, in NASH patients with fibrosis during 2H 2017
December 28, 2016: Hearing takeover rumors about biotechnology firm Intercept Pharmaceuticals. The rumor is that Novartis could be a potential acquirer. Can not find the source of the rumors. StreetInsider asked an Intercept Pharmaceuticals spokesperson about the rumor and the company said it will not comment on M&A speculation.
Intercept Pharmaceuticals Stock Chart
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases.
Latest posts by Lance Jepsen (see all)
- S&P 500 Index Does Breakout, 2500 Next - May 28, 2017
- IMAX Theaters Goes Into Virtual Reality as M&A Talk Picks Up - May 28, 2017
- How High Bitcoin Go 2017, Many Say $10,000 - May 28, 2017